Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical compositions and methods

A composition and drug technology, applied in the direction of drug combination, pharmaceutical formula, heterocyclic compound active ingredients, etc., can solve the problems of resistance, expensive treatment, inaccuracy, etc.

Active Publication Date: 2017-11-03
TYME
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] While all of these treatments are effective to varying degrees, they all have drawbacks and limitations
As well as many treatments being expensive, they are often either too imprecise or the cancer can adapt to them and become resistant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions and methods
  • Pharmaceutical compositions and methods

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0059] A clinical study was conducted to evaluate the effectiveness, safety, acceptability and tolerability of combination therapy according to embodiments of the present invention as a therapy for metastatic cancer.

[0060] This combination therapy includes the following:

[0061] (a) Capsules containing melanin (50mcg) and α-methyl-DL-tyrosine (75mg) for oral administration;

[0062] (b) Capsules containing 5,5-diphenylhydantoin (15 mg) and α-methyl-DL-tyrosine (75 mg) for oral administration;

[0063] (c) Capsules containing 5,5-diphenylhydantoin (15 mg) and α-methyl-DL-tyrosine (75 mg) for oral administration;

[0064] (d) Capsules containing rapamycin (0.2 mg) and α-methyl-DL-tyrosine (75 mg) for oral administration;

[0065] (e) a suspension containing rapamycin (0.15mcg), melanotan II (10mcg) and 5,5-diphenylhydantoin (2mg), administered subcutaneously; and

[0066] (f) Suspension containing α-methyl-DL-tyrosine (5 mg) in NaCl bacteriostatic water, administered subc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides pharmaceutical compositions and kits comprising tyrosine hydroxylase inhibitors; melanin, melanin promoters or combinations thereof; p450 3A4 promoters; and leucine Acid aminopeptidase inhibitors. Also provided is a method of treating cancer in a subject comprising administering to it an effective amount of a tyrosine hydroxylase inhibitor, a melanin booster, a p450 3A4 booster, and a leucine aminopeptidase inhibitor Subjects in need. Also provided is a method of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin enhancer, a p450 3A4 enhancer, and a leucine aminopeptidase inhibitor to the its subjects in need.

Description

[0001] Cross references to related patent applications [0002] This application is a continuation-in-part of US Patent Application No. 13 / 371,076, filed February 10, 2012, which claims priority to US Provisional Patent Application No. 61 / 587,420, filed January 17, 2012. This application also claims priority to US Provisional Patent Application No. 61 / 702,994, filed September 19, 2012. All applications mentioned in this paragraph are hereby incorporated by reference in their entirety. technical field [0003] The present application relates generally to compositions, kits and methods for reducing cell proliferation, such as, for example, in cancer treatment. Background technique [0004] According to the U.S. National Cancer Institute's Surveillance Epidemiology and End Results (SEER) database in 2008 (the most recent year for which incidence data are available), 11,958,000 Americans had invasive cancer. Cancer is the second most common cause of death in the United States ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/195A61K38/00A61P35/00
CPCA61K31/19A61K31/198A61K31/37A61K31/4166A61K31/436A61K31/55A61K38/34A61K2300/00A61K38/31A61K31/20A61P35/00
Inventor 斯蒂文·霍夫曼
Owner TYME
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com